Language disturbances as a side effect of prophylactic treatment of migraine.
BACKGROUND
Language disturbances have been previously described as word-finding difficulties in epileptic patients. These disturbances have been recently reported in migraineurs in treatment with topiramate but they have never been defined and assessed in these patients with the aid of neuropsychological testing.


OBJECTIVE
To verify the occurrence of language disturbances as a side effect of topiramate treatment in episodic and chronic migraine patients.


METHODS
Language disturbances were recorded on the basis of spontaneous reports of 30 migraine patients treated with topiramate and 2 control groups (20 patients treated with other prophylactic drugs and 20 patients without prophylactic treatment) and were explored with neuropsychological tests. Psychiatric comorbidity was assessed using Zung Anxiety and Depression Scales.


RESULTS
Language disturbances were referred by 26.7% (n=8) of patients during topiramate treatment but by none of the patients in the 2 control groups. All patients in the topiramate group had a worse performance on all tests compared to patients of the 2 control groups. Moreover, in the topiramate group, patients with referred language disturbances had higher scores for all neuropsychological test variables, indicative of a worse performance. Some language functions (Trail Making Tests A and B) seemed to be influenced by the concomitant presence of psychiatric comorbidities, particularly anxiety and depression.


CONCLUSIONS
It can be hypothesized that a disorder such as migraine, which involves numerous cortical and subcortical circuits implicated in the transmission and behavioral and emotional processing of pain, represents a facilitated substrate for the occurrence of language disturbances due to topiramate. This could be the expression of a more generalized impairment of cognitive processing. These aspects should be investigated in prospective studies involving larger migraine patient samples.
Coppola
Francesca
F
Neurologic Clinic, Department of Medical and Surgical Specialties and Public Health, University of Perugia, Italy.
Rossi
Cristiana
C
Mancini
Maria Luisa
ML
Corbelli
Ilenia
I
Nardi
Katiuscia
K
Sarchielli
Paola
P
Calabresi
Paolo
P
D000328:Adult; D000704:Analysis of Variance; D005260:Female; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D007806:Language Disorders / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000009:adverse effects*; D009483:Neuropsychological Tests; D011569:Psychiatric Status Rating Scales; D000077236:Topiramate
D018696:Neuroprotective Agents; D000077236:Topiramate; D005632:Fructose